Patents Expiring in July 2029
✉ Email this page to a colleague
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | METHOD OF POSITRON EMISSION TOMOGRAPHY (PET) IN MEN WITH PROSTATE CANCER | ||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-001 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-002 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-003 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-004 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-005 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |